menu
    • menu
    [{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Boxer Capital"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"INX-315","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Not Applicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INX-315","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Incyclix Bio

    Menu

    Incyclix Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Incyclix Shares Interim Phase 1/2 Data of INX-315 in CDK4/6 Resistant Breast Cancer

    Details : INX-315 is a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant for the treatment of HR+/HER2- Breast Cancer.

    Product Name : INX-315

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 13, 2024

    Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Eli Lilly

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Incyclix Bio Collaborates with Lilly to Evaluate INX-315 in HR+/HER2- Breast Cancer

    Details : The collaboration aims to evaluate INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio (abemaciclib) and fulvestrant in HR+/HER2- Breast Cancer.

    Product Name : INX-315

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 18, 2024

    Lead Product(s) : INX-315,Abemaciclib,Fulvestrant

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Eli Lilly

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INX-315

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Adva...

    Details : INX-315 is a novel, potent and selective inhibitor of CDK2 to treat patients whose tumors are insensitive to CDK4/6 inhibition, either by primary resistance or acquired resistance due to prior treatment with a CDK4/6 inhibitor.

    Product Name : INX-315

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    February 28, 2023

    Lead Product(s) : INX-315

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed

    Incyclix Bio

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INX-315

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Boxer Capital

    Deal Size : $30.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

    Details : Proceeds from the financing will be used to support the clinical development of Incyclix Bio’s lead compound, INX-315, a novel, potent and selective CDK2 inhibitor with compelling preclinical efficacy and safety data.

    Product Name : INX-315

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    March 31, 2022

    Lead Product(s) : INX-315

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Boxer Capital

    Deal Size : $30.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth